The aim of the present study was to evaluate the in vivo effects of the RAR-a selective antagonist Ro 41-5253 on a xenograft
animal model for breast cancer. Our observations indicate a lack of toxic side effects of the drug, even when used at high
dosages. It is interesting to note that using Ro 41-5253 at dosages of 10, 30 and 100 mg/kg/die resulted in a slight, but significant
inhibition of cell growth. The data obtained in this study represents the basis for a further evaluation of Ro 41-5253
anti-neoplastic activity on transgenic breast cancer animal models.
q 2004 Elsevier Ireland Ltd. All rights reserved
